• PDF / 169,789 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 47 Downloads / 173 Views

DOWNLOAD

REPORT

---

1 S

Lack of efficacy: 4 case reports In a retrospective study conducted from January 2010 to October 2019, involving 40 women, 4 women aged 21–41 year were described, who exhibited lack of efficacy while receiving treatment with warfarin, aspirin or mycophenolate mofetil for LibmanSacks (LS) endocarditis [routes and dosages not stated]. Patient 3: A 24-year-old woman, who had a history of systemic lupus erythematosus (SLE), had been receiving unspecified highdose steroids and immunosuppressive therapy with azathioprine. On further examination, she was diagnosed with LS endocarditis manifested as catastrophic antiphospholipid syndrome (CAPS). She started receiving treatment with warfarin; however, no change in LS endocarditis (CAPS) were noted. Patient 4: A 21-year-old woman, who had a history of neuropsychiatric SLE, had been receiving unspecified high-dose steroids and immunosuppressive therapy with mycophenolate mofetil that showed initial improvement. On further examination, she was diagnosed with LS endocarditis. Five months later, despite treatment with mycophenolate mofetil for LS endocarditis, she developed cerebral infarction. Patient 7: A 41-year-old woman, who had a history of SLE, was diagnosed with LS endocarditis. Subsequently, she started receiving treatment with warfarin and aspirin; however, there were no changes in LS endocarditis. Patient 9: A 23-year-old woman, who had a history of SLE, received heparin during pregnancy. Following pregnancy, she was diagnosed with LS endocarditis and received treatment with warfarin; however, no changes were noted in the LS endocarditis. Yoo B-W, et al. Clinical characteristics and long-term outcomes of Libman-Sacks endocarditis in patients with systemic lupus erythematosus. Lupus 29: 1115-1120, No. 9, Aug 2020. Available from: URL: http://doi.org/10.1177/0961203320930097 803510188

0114-9954/20/1828-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 31 Oct 2020 No. 1828